CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：Barriers to Chimeric Antigen Receptor T-Cell (CAR-T) Therapies in Clinical Practice.
Barriers to Chimeric Antigen Receptor T-Cell (CAR-T) Therapies in Clinical Practice.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
CAR-T 细胞疗法是一种革命性癌症治疗方式，采集患者自身T细胞并在体外进行工程化改造，使其表达嵌合抗原受体（CAR）。这些重新编程的CAR-T 细胞回输至同一患者后，会刺激T细胞介导的免疫应答，靶向表达抗原的恶性细胞并导致其死亡。CAR-T 药物关键性临床试验的初始结果令人鼓舞，多个产品已获批用于复发性血液系统恶性肿瘤，包括急性淋巴细胞白血病（ALL）、弥漫大B细胞淋巴瘤（DLBCL）、套细胞淋巴瘤、滤泡性淋巴瘤，以及近期获批的多发性骨髓瘤。然而，自初始试验和美国食品药品监督管理局批准后，该疗法广泛应用仍面临重大障碍，包括复杂的流程、生产限制、毒性顾虑和经济负担。本文讨论可能克服这些障碍的方案，以使这一改变生命的治疗能够广泛应用。
Chimeric antigen receptor T-cell (CAR-T) therapy is a revolutionary cancer treatment modality where a patient's own T cells are collected and engineered ex vivo to express a chimeric antigen receptor (CAR). These reprogrammed CAR-T cells, when reinfused into the same patient, stimulate a T-cell mediated immune response against the antigen-expressing malignant cells leading to cell death.
The initial results from pivotal clinical trials of CAR-T agents have been promising, leading to multiple approvals in various hematologic malignancies in the relapsed setting, including acute lymphoblastic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma, follicular lymphoma, and, more recently, multiple myeloma.
However, since the initial trials and US Food and Drug Administration approvals, there have been significant barriers to the widespread use of this therapy. The barriers to the use of CAR-T therapy include complex logistics, manufacturing limitations, toxicity concerns, and financial burden. This review discusses potential solutions to overcome these barriers in order to make this life-changing therapy widely accessible.
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。
